Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) EBT (2016 - 2025)

Lisata Therapeutics' EBT history spans 13 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, EBT rose 35.92% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached -$17.5 million, up 15.57%, while the annual FY2025 figure was -$17.5 million, 15.57% up from the prior year.
  • EBT reached -$3.0 million in Q4 2025 per LSTA's latest filing, up from -$4.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$3.0 million in Q4 2025 to a low of -$6.4 million in Q2 2023.
  • Average EBT over 3 years is -$5.1 million, with a median of -$5.2 million recorded in 2023.
  • Peak YoY movement for EBT: decreased 0.19% in 2024, then surged 35.92% in 2025.
  • A 3-year view of EBT shows it stood at -$5.4 million in 2023, then grew by 14.07% to -$4.6 million in 2024, then soared by 35.92% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's EBT are -$3.0 million (Q4 2025), -$4.2 million (Q3 2025), and -$4.7 million (Q2 2025).